Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Theracryf Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Theracryf şirketinin toplam hissedar öz sermayesi £2.3M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £3.1M ve £721.0K dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£2.00m
Eşitlik	UK£2.34m
Toplam yükümlülükler	UK£721.00k
Toplam varlıklar	UK£3.06m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

Recent updates

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TCF 'nin kısa vadeli varlıkları ( £3.0M ) kısa vadeli yükümlülüklerini ( £723.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: TCF 'un kısa vadeli varlıkları ( £3.0M ) uzun vadeli yükümlülüklerini ( £-2.0K ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TCF borçsuzdur.

Borcun Azaltılması: TCF un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TCF son raporlanan serbest nakit akışına göre 8 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: TCF serbest nakit akışı her yıl % 8 1.7 yıl yetecek nakit akışına sahip olacaktır.

Theracryf Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Recent updates

New major risk - Share price stability

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

New minor risk - Share price stability

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

New minor risk - Share price stability

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Consensus revenue estimates fall by 92%

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Consensus forecasts updated

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin